About Lucigen
Lucigen is a Healthcare company based in Middleton (United States) founded in 1998, and was acquired by LGC in February 2018. Lucigen is engaged in developing molecular biology enzymes and reagents. It operates on a Professional Services and Direct-to-Consumer (D2C) model. Lucigen has raised $3.93 million across 7 funding rounds from investors including LGC, National Science Foundation and HHS. Lucigen offers products and services including QuickExtract DNA Extraction Solution, NxGen T7 RNA Polymerase, and Endura Competent Cells. Its focus areas include Biotechnology, Molecular Biology, Diagnostics and Molecular Diagnostics. Its legal entity is LGC, Biosearch Technologies. Its competitors include Neogen, RareCyte and PrognomiQ; 3 of its 3 listed competitors have raised funding.
Company details
Lucigen, part of LGC Biosearch Technologies, is focused on the development, manufacturing, and supply of molecular biology enzymes, reagents, and kits. The company serves sectors such as clinical diagnostics, drug discovery, synthetic biology, and gene editing. Solutions are provided for nucleic acid extraction, PCR and qPCR reagents, next-generation sequencing kits, and competent cells for transformation. Operations are supported by a skilled workforce and ISO-13485 certified manufacturing capabilities, ensuring high-quality products for life science professionals globally.
- Headquarters Middleton, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website lucigen.com
- Social LinkedIn X Facebook
- Acquired by LGC (Feb 2018)
- Legal Name Lgc, Biosearch Technologies
Products & Services of Lucigen
Lucigen offers a comprehensive portfolio of products and services, including QuickExtract DNA Extraction Solution, NxGen T7 RNA Polymerase, and Endura Competent Cells.
DNA extraction solution is provided for rapid processing.
RNA polymerase is offered for in vitro transcription.
Competent cells are supplied for transformation applications.
Funding Insights of Lucigen
Lucigen has successfully raised a total of $3.93M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $2.23 million completed in March 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.93M
- Total Rounds 7
- Last Round Series A — $2.23M
- First Round $864,610
(Jan 2005)
- Investors Count 2
All 7 funding rounds of Lucigen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2015 | $2.23M | Series A | – | – | – |
| Aug 2012 | $1.7M | Series A | – | – | – |
| Sep 2010 | $1.46M | Grant | – | – | |
| Jun 2009 | $100,000 | Grant | – | – | |
| Apr 2009 | $300,000 | Grant | – | – | |
| Feb 2005 | $50,000 | Unspecified | – | – | – |
| Jan 2005 | $864,610 | Unspecified | – | – | – |
3 investors in total: 3 institutional.
Investors in Lucigen
Lucigen has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include LGC, National Science Foundation and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States | |
| hhs.gov | ||||
Molecular biology reagents and services are supplied to biotech industries. | 1842 | lgcgroup.com | Teddington, United Kingdom |
Investor details for Lucigen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Lucigen
4 dated milestones of Lucigen across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Lucigen is founded.
- Funding First funding round of $865K.
- Funding Latest funding round, Series A, of $2.2M.
- Exit Acquired by LGC.
Competitors of Lucigen
Lucigen has 3 listed competitors in our database, 3 of them funded. They include Neogen, RareCyte and PrognomiQ.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neogen.com | 1982 | Lansing, United States | $700,000 | 2,640 | Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing | |
| rarecyte.com | 2009 | Seattle, United States | $114.33M | 54 | Developer of technologies for the analysis of rare and single cells in the blood | |
| prognomiq.com | 2020 | San Mateo, United States | $90.36M | 24 | Developer of tests for the detection and treatment of cancer and other diseases |
Detailed competitors of Lucigen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Lucigen
Websites that share an audience with Lucigen (lucigen.com).
Websites whose visitors overlap most with Lucigen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| epibio.com | 100% | View details | |||
promega.com | promega.com | 91% | #192,389 | – | |
| kpl.com | 88% | View details | |||
| qiagen.com | 86% | 458.2K | #105,023 | View details | |
biotechprofiles.com | biotechprofiles.com | 85% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 23 similar websites and full traffic analytics for Lucigen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 23 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Lucigen (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lucigen
Complete news archive for Lucigen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lucigen
Lucigen was founded in 1998 and raised its 1st funding round 7 years after it was founded.
Lucigen is headquartered in Middleton, United States.
Lucigen is a funded company, having raised a total of $3.93M across 7 funding rounds to date. The company's 1st funding round was a Unspecified of $864.61K, raised on Jan 2005.
Lucigen, part of LGC Biosearch Technologies, is focused on the development, manufacturing, and supply of molecular biology enzymes, reagents, and kits. The company serves sectors such as clinical diagnostics, drug discovery, synthetic biology, and gene editing. Solutions are provided for nucleic acid extraction, PCR and qPCR reagents, next-generation sequencing kits, and competent cells for transformation. Operations are supported by a skilled workforce and ISO-13485 certified manufacturing capabilities, ensuring high-quality products for life science professionals globally.
Lucigen offers QuickExtract DNA Extraction Solution, NxGen T7 RNA Polymerase, and Endura Competent Cells.
Lucigen has 3 investors. Key investors include LGC, National Science Foundation, and HHS.
Lucigen operates through Lgc, Biosearch Technologies.
Yes. Lucigen was acquired by LGC in February 2018.